Henovcom Bioscience Co., Ltd. was founded in 2013. Drawing on the extensive experience of the founders and the core team in nucleoside modifications and nucleic acid chemistry, Henovcom has developed the novel and highly efficient mRNA capping agent LZCap® for the "one-pot" IVT of mRNA. It has also developed other novel modified nucleotides for mRNA synthesis at both research and commercial scales. Additionally, Cy5 or Cy7 labeled LZCaps offer a unique and efficient means for tracing the mRNA and the transduction/distribution of LNP both in vitro and in vivo. Novel ionizable lipids have been developed with good profile for large and repeated dosing of mRNA LNP. Henovcom has established a state - of - the - art GMP facility and obtained ISO 9001 certification for the production of mRNA raw materials and lipids.

Henovcom also provides technical services related to RNA and delivery systems, which include customized nucleoside modification, the preparation of LZCap capped mRNA/saRNA, the screening of ionizable lipids using fluorescent labeled LZCap capped target mRNA, LNP encapsulation and assay, antibody conjugated LNP for in vivo T cell engineering, as well as the development and production of novel ionizable lipids. Henovcom's technical platform and innovative mRNA related raw materials will continue to provide customized optimal solutions for customers' development of mRNA therapeutics.

en.henovcom.com